| 產(chǎn)品編號 | BIO0977SM |
| 英文名稱 | Anti-TNFalpha & IL17 Reference Antibody (Remtolumab Biosimilar) |
| 別 名 | IL-17 / IL-17A / CTLA-8 & TNF-alpha; Remtolumab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 198.56kDa |
| 性 狀 | Lyophilized |
| 亞 型 | DVD-Ig |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Remtolumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Remtolumab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 0.130 nM.
Remtolumab bound to huTNFα-CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Remtolumab bound to huTNFα-CHO-K cells, and the EC50 was 148.700 nM.
Remtolumab bound to TNFα protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Remtolumab bound to hu-TNFα-Fc , and the EC50 was 0.027 nM.
Remtolumab bound to IL-17a protein, and then rebounded to secondary antibodies (human-IgG-Fc-HRP) , and read OD450. As shown in fig, Remtolumab bound to huIL-17a-His , and the EC50 was 0.072 nM.
The purity of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 100.00%, determined by SEC-HPLC.
Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected weight of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 198.49 kDa.
|
